Article

Pharma Validation for Human-AI Workflow Change

2026-09-02

Pharma Validation for Human-AI Workflow Change

A validation-minded approach to redesigning regulated workflows with AI assistance.

The operating problem

AI can accelerate analysis and implementation, but regulated change still needs intended use, controlled inputs, testable requirements, independent review, traceability, and approved release. Generated confidence is not validation.

What the review should cover

• Define intended use and prohibited use
• Control the evidence admitted into design
• Translate obligations into testable acceptance criteria
• Keep builder and quality review responsibilities distinct
• Retain the validation and closeout package

Start with a real scenario

Start with one bounded workflow where the current process, sources, exceptions, and quality decisions can be made explicit. Use the pilot to measure evidence completeness and review effort, not to claim broad automation.

Where JarviSIM and JSWARM fit

JarviSIM's closed beta focuses on evidence-grounded process design and source governance. JSWARM supplies a repeatable Human-AI delivery cycle. LSA Digital connects them through a practical workflow session.

Practical next step

Bring one validation-sensitive workflow to a Human-AI design briefing.

LSA Digital's approach is to start with bounded work, visible evidence, and human accountability. Public claims should reflect pilot evidence as it is established, not assume results before deployment.